For the first time, tTMB, bTMB and KRAS mutations appear to be independent validated IRPSs of the clinical outcome for Qujing advanced NSCLC populations, and bTMB may be used as a reliable IRPS that predicts the clinical benefit from ICIs among Qujing populations with advanced NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.